Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX)’s stock price rose 10% during trading on Monday . The stock traded as high as $0.26 and last traded at $0.25, approximately 256,054 shares traded hands during trading. A decline of 42% from the average daily volume of 442,030 shares. The stock had previously closed at $0.23.
PLX has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. Zacks Investment Research upgraded shares of Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its earnings results on Thursday, August 8th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.02). The company had revenue of $12.25 million for the quarter, compared to analysts’ expectations of $11.75 million. During the same period in the prior year, the firm posted ($0.08) EPS.
A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC raised its holdings in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 7.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,326,528 shares of the company’s stock after buying an additional 308,823 shares during the quarter. Renaissance Technologies LLC owned 2.92% of Protalix Biotherapeutics worth $2,029,000 as of its most recent SEC filing.
About Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Story: Bear Market
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.